



SYSTIMMUNE

Abstract Number:
2642

BL-B01D1, a novel EGFR×HER3-targeting ADC, demonstrates robust anti-tumor efficacy in preclinical evaluation

Weili Wan, Shuwen Zhao, Shi Zhuo, Yong Zhang, Lan Chen, Gangrui Li, Blair Renshaw, Jahan Salar Khalili, Sa Xiao, Yi Zhu. Sichuan Baili Pharmaceutical Co., Ltd., Chengdu, China, SystImmune Inc., Redmond, WA

Abstract


EGFR and HER3, members of the human epidermal growth factor receptor (ErbB) family, are targeted in cancer therapy due to their over-expression and pathway dependence in common human epithelial carcinoma tumors. To develop a promising therapeutic anti-tumor agent, we generated BL-B01D1, an EGFR×HER3-targeting ADC, which can bind to EGFR and/or HER3 positive cells and is expected to be superior to anti-EGFR and anti-HER3 ADCs. It is comprised of a bispecific antibody against EGFR/HER3 (SI-B001), a cathepsin B cleavable linker, and a novel topoisomerase I inhibitor agent (Ed-04), which is a derivative of the alkaloid camptothecin, driving cell cycle arrest at the S phase and subsequent apoptosis. BL-B01D1 achieves a high drug-to-antibody-ratio (DAR=8) with a highly stable linker.

The pharmacological potential of this ADC was evaluated in comparison to its parental single antigen-targeting ADCs in xenograft models composed of either the human colorectal cancer cell line SW620 or pancreatic cancer cell line BxPC3. The tumor inhibition activity of BL-B01D1 was compared with ADCs prepared from each parental anti-EGFR or anti-HER3 mAb conjugated with the same linker and payload. The bispecific ADC, BL-B01D1 exhibited stronger tumor inhibition capacity than the anti-EGFR ADC and the anti-HER3 ADC separately.

The preclinical studies suggest BL-B01D1, as an EGFR×HER3-targeting ADC, might be a promising novel agent with activity toward a broad range of human cancers. The clinical phase I has been progressing and the available data exhibit excellent efficacy but low levels of targeted toxicity in the non-small cell lung cancer (NSCLC) treatment setting. Overall, these data suggest BL-B01D1 has potential to serve as a novel, efficacious therapeutic agent for NSCLC with similar therapeutic impact as DS-8201 has in breast cancer treatment.

Therapeutic Mechanism of Action

H I R E



BL-B01D1 Cell Binding is determined by EGFR and not HER3






Figure 1. BL-B01D1 structure mediates specific antigen binding and multi-domain target mediated cytolytic function. ASPC-1 cells (EGFR+HER3+), ES-2 cells (EGFR+,HER3-) and MCF-7 cells (EGFRlo, HER3+) were used to test BL-B01D1 binding to cells with differential expression of target antigens. These results indicate that BL-B01D1 does not bind effectively to Cells with very low EGFR, despite expression of HER3. The antigen density of HER3 is lower than EGFR in the cell lines tested

BL-B01D1 Bi-specific ADC



BL-B01D1 proliferation inhibition is mediated by EGFR and HER3 binding and Ed-04 specific cytotoxicity in vitro

A Cetuximab Sensitive Cell Lines B Cetuximab Insensitive Cell Lines



HER3 activity: Direct Growth suppression and enhancement of payload delivery

- BL-B01D1 parental bi-specific antibody, SI-B001, demonstrates greater tumor control vs Parental EGFR IgG alone
- BL-B01D1 potency is increased vs Parental EGFR ADC

Ed-04 activity: Present in EGFR sensitive and insensitive cell lines

- In Cetuximab sensitive cell lines, BL-B01D1 improves efficacy compared to SI-B001, demonstrating Ed-04 contribution to cytotoxicity

Figure 2. BL-B01D1 specific cytotoxicity to cancer cell lines in vitro. Cetuximab sensitive and Cetuximab insensitive cell lines were treated with either SI-B001 the parental bi-specific of BL-B01D1, the anti-EGFR mAb Cetuximab, BL-B01D1 or the ADC composed of Cetuximab and Ex0115.

comparison to its parental single antigen-targeting ADCs

BL-B01D1 shows superior control of Xenograft Tumor growth in vivo




Figure 3. BL-B01D1 comparative testing in tumor xenograft models. Payload comparison (A). Bi-specific parental component comparison and comparator evaluation (B-D)

Heterogenous EGFR Xenograft Tumor Control by BL-B01D1 in vivo




Figure 4. BL-B01D1 comparative testing in EGFR heterogeneous tumor xenograft models. Payload comparison (A,B)

Summary

- BL-B01D1, an EGFR×HER3-targeting ADC, which can bind to EGFR and/or HER3 positive cells
- BL-B01D1 is comprised of a bispecific antibody against EGFR/HER3 (SI-B001), a cathepsin B cleavable linker, and a novel topoisomerase I inhibitor agent (Ed-04) with a drug-to-antibody-ratio of 8 (DAR=8)
- Ed-04 is a derivative of the alkaloid camptothecin, driving cell cycle arrest at the S phase and subsequent apoptosis showing superior bystander activity compared to Daichi payload (in house)
- BL-B01D1 exhibited stronger tumor inhibition capacity than the parental anti-EGFR ADC and the anti-HER3 ADC in colorectal cancer SW620 and pancreatic cancer BxPC3 xenograft models
- As an EGFR×HER3-targeting ADC, BL-B01D1 might be a promising, novel agent, with activity toward a broad range of human cancers

Acknowledgments

The authors acknowledge the efforts and contributions of numerous staff of SystImmune Inc. and Bai-li Pharmaceuticals who worked on the development of BL-B01D1

References

- BL-B01D1 clinical trials:
 - Title: A Clinical Study of BL-B01D1 in Patients With Multiple Solid Tumors Such as Recurrent or Metastatic Gynecological Malignancies
 - Title: A Clinical Study of BL-B01D1 in Patients With Multiple Solid Tumors Such as Locally Advanced or Metastatic Urinary System Tumors
 - Title: A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
 - Title: A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Solid Tumor
 - Title: A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Urological Tumors and Other Solid Tumors
 - Title: A Study of BL-B01D1 in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer and Other Solid Tumors

URL
<https://ClinicalTrials.gov/show/NCT05803018>
<https://ClinicalTrials.gov/show/NCT05785039>
<https://ClinicalTrials.gov/show/NCT05262491>
<https://ClinicalTrials.gov/show/NCT05194982>
<https://ClinicalTrials.gov/show/NCT05393427>
<https://ClinicalTrials.gov/show/NCT05470348>